Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANKU-NPC02 phase III maintenance study of BL-B01D1 plus PD-1 inhibitor after PD-1 inhibitor plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma
CTR20263234Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan, toripalimab, gemcitabine, cisplatin in nasopharyngeal carcinoma (NPC), sponsored by Biokin Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
izalontamab brengitecantoripalimabgemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20263234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263234.